Home

Dolutegravir/rilpivirine

Dolutegravir-rilpivirine is a two-drug, single-tablet regimen that may be used to replace an existing antiretroviral regimen in persons who have suppressed HIV RNA levels on a stable antiretroviral regimen for at least 6 months; the dolutegravir-rilpivirine two-drug regimen should only be used in persons with no history of antiretroviral treatment failure and no known mutations associated with resistance to either dolutegravir or rilpivirine Juluca contains two different medicines: dolutegravir and rilpivirine. HIV medicines can't cure HIV/AIDS, but taking HIV medicines every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission Dolutegravir/rilpivirine (Juluca ®) is the first two-drug single-tablet regimen (STR) to be approved for the treatment of HIV-1 infection in adults. The fixed-dose STR combines the integrase strand transfer inhibitor dolutegravir with the non-nucleoside reverse transcriptase inhibitor rilpivirine The safety profiles of both dolutegravirand rilpivirinewere consistent with the respective labels. A dolutegravirplus rilpivirine[2-drug regimen] offers the potential for reduction in cumulative ART exposure, without an increased risk of virologic failure. Dolutegravirand Inhibition of Tubular Secretion of Creatinin

drug-exposure, toxicities, and costs. Dolutegravir (DTG) 50 mg/rilpivirine (RPV) 25 mg was approved in November 2017 by FDA and in May 2018 by the European Medicines Agency (EMA). It is indicated as a complete regimen for HIV-1 infected adults with undetectable plasmatic HIV-RNA for at least 6 months on their curren Dolutegravir and rilpivirine is a combination antiviral medicine used to treat HIV, the virus that can cause the acquired immunodeficiency syndrome (AIDS). dolutegravir and rilpivirine is not a cure for HIV or AIDS

Official DOVATO (dolutegravir - /lamivudine) - HCP Websit

  1. Concomitant use of dolutegravir/rilpivirine and other drugs may result in known or potentially significant drug interactions, loss of therapeutic effect of dolutegravir/rilpivirine, possible..
  2. One of the medicines in JULUCA, called dolutegravir, may harm your unborn baby. Your healthcare provider may prescribe a different medicine than JULUCA if you are planning to become pregnant or if pregnancy is confirmed during the first 12 weeks of pregnancy
  3. imise cumulative drug exposure and toxicities. The safety, tolerability, and efficacy of dolutegravir and rilpivirine suggest potential compatibility and effectiveness as a two-drug regimen

This antiinfective drug article is a stub. You can help Wikipedia by expanding it Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 July 2021), Cerner Multum™ (updated 1 July 2021), ASHP (updated 30 June. Each tablet contains: 50 mg of dolutegravir (equivalent to 52.6 mg dolutegravir sodium) and 25 mg of rilpivirine (equivalent to 27.5 mg rilpivirine hydrochloride). (3

Each film-coated tablet contains 50 mg of dolutegravir (equivalent to 52.6 mg dolutegravir sodium) and 25 mg of rilpivirine (equivalent to 27.5 mg rilpivirine hydrochloride). 4 Dolutegravir/rilpivirine is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV.. Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non. ↔Dolutegravir ↓Rilpivirine: JULUCA should only be administered at least 4 hours before or 12 hours after taking H 2-receptor antagonists. Herbal product: St John's wort (Hypericum perforatum) ↓ Dolutegravir ↓Rilpivirine: Coadministration is contraindicated with JULUCA due to decreased rilpivirine concentrations [see CONTRAINDICATIONS] Dolutegravir/rilpivirine (DTG/RPV) (Juluca) is an oral single-tablet regimen indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV ribonucleic acid [RNA] < 50 copies/mL)

Dolutegravir-Rilpivirine Juluca - Treatment - National HIV

dolutegravir/rilpivirine is a topic covered in the Davis's Drug Guide.. To view the entire topic, please log in or purchase a subscription.. Davis's Drug Guide for. The combination of dolutegravir + rilpivirine has been studied in two parallel randomized open-label Phase III switch studies in patients on a stable 3-drug antiretroviral regimen. Subjects had to have had HIV RNA levels of <50 copies/mL for at least 12 months, no history of virologic failure, and no resistance to antiretroviral medications Video stories. Hello, Undetectable you. Watch the stories of inspiring individuals who are HIV positive and undetectable.*. *Undetectable means keeping the amount of HIV-1 in the blood at very low levels (less than 50 copies per mL). All people featured on this site are real patients diagnosed with HIV-1 Sex Transm Infect. 2021 Mar 29;sextrans-2020-054821. doi: 10.1136/sextrans-2020-054821. Online ahead of print

Dolutegravir / Rilpivirine - Patient NI

  1. The INSTI dolutegravir binds to the active site of HIV integrase, thereby blocking the strand transfer step of retroviral DNA integration (an essential part of the HIV replication cycle) [8, 9].Rilpivirine, a diarylpyrimidine NNRTI, inhibits HIV-1 replication by non-competitively inhibiting the reverse transcriptase of HIV-1
  2. The MarketWatch News Department was not involved in the creation of this content. Jul 01, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry..
  3. Dolutegravir / rilpivirine film-coated tablet (Juluca®) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI) (September 2018
  4. Dolutegravir and rilpivirine is a combination antiviral medicine used to treat HIV, the virus that can cause the acquired immunodeficiency syndrome (AIDS). This medicine is not a cure for HIV or AIDS. Dolutegravir and rilpivirine is for use only in people who have been successfully treated with other antiviral medications for at least 6 months
  5. Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators
  6. The fixed-dose combination of dolutegravir / rilpivirine (trade name: Juluca) has been approved in Germany since May 2018 for the treatment of type 1 HIV in adults. It can be used in people who are already receiving successful treatment against the virus

Learn more about JULUCA (dolutegravir 50 mg/rilpivirine 25 mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1). NLM Identifier: NCT . Market Applicability Market DC GA KY MD NJ NY WA Applicable NA X X X X NA NA PAGE 2 of 2 03/01/2020. Comparison of a Two-Drug Regimen (Dolutegravir/Rilpivirine) to Standard Three-Drug Regimens in Virologically Suppressed, Treatment Experienced Individuals in the Real. All Interactions with Dolutegravir (Tivicay) Administer dolutegravir 2 hours before or 6 hours after antacids. Do not coadminister simultaneously. Administer dolutegravir 2 hours before or 6 hours after antacids. Dolutegravir AUC decreased ~39% if taken together, fasting conditions

Dolutegravir/Rilpivirine: A Review in HIV-1 Infectio

Policy: Antivirals: HIV Combinations Medical Policy No. 12.10.99-2 Last Updated 03/01/2021 1 Antivirals - HIV Combinations Medical policy no. 12.10.99-2 Effective Date: August 1, 202 dolutegravir / rilpivirine) An overview of Juluca and why it is authorised in the EU . What is Juluca and what is it used for? Juluca is a medicine used to treat adults infected with human immunodeficiency virus -1 (HIV-1), a virus that causes acquired immune deficiency syn drome (AIDS) Dolutegravir + rilpivirine FDC is an oral tablet that contains two antiretroviral medicines: 1,3 dolutegravir 50 mg and ; rilpivirine 25 mg. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that prevents HIV replication by stopping HIV DNA from integrating into the nucleus of the host cell. 4,5 Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that reduces.

Coronavirus update: Important OptumRx updates to support providers, clinical staff and patients through COVID-19 Dolutegravir & Rilpivirine CNS Penetration A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, ART-Naive Subjects....

All you pay is a set service fee of $50 for each medication per month. This includes 100% of the medication cost, no matter the retail price. Prescription Hope is NOT a prescription discount card or an insurance plan. Prescription Hope works with over 180 U.S.-based pharmaceutical manufacturers patient assistance programs to access over 1,500. More participants taking dolutegravir-rilpivirine (17 [3%]) reported adverse events leading to withdrawal than did participants taking CAR (three [<1%]). Interpretation Dolutegravir-rilpivirine was non-inferior to CAR over 48 weeks in participants with HIV suppression and showed a safety profile consistent with its components Issued: London, UK. Juluca is a two-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide 2, and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson). 3 The distribution and sales operations of the once-daily single-pill regimen will be conducted by GlaxoSmithKline K.K. Tokyo, in the same. Dolutegravir; rilpivirine plasma concentrations are decreased in patients with severe renal impairment and caution is advised when administering the drug to patients with renal failure (CrCl less than 30 mL/min) and/or end-stage renal disease. Use in this patient population may result in loss of therapeutic effect and development of resistance dolutegravir / rilpivirine 11/06/2020 n/a PRAC Recommendation - maintenance WS/1762 This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.3 and 4.5 of the SmPC in order to add a new contraindication in relation to the co

Juluca (Dolutegravir, Rilpivirine) : Side Effects, Dosage

Dolutegravir + rilpivirine Published 2nd January 2016, updated 19th November 2020. Dolutegravir + Rilpivirine Infection and infectious diseases Medicine NHS England commissioned Patent Expiries. dm+d. 35555911000001100 Rate this page. Let us know whether our content met your needs by rating this page dolutegravir/rilpivirine is a topic covered in the Davis's Drug Guide.. To view the entire topic, please log in or purchase a subscription.. Anesthesia Central is an. WebMD provides common contraindications for dolutegravir-rilpivirine oral. Find out what health conditions may be a health risk when taken with dolutegravir-rilpivirine ora dolutegravir/rilpivirine is a topic covered in the Davis's Drug Guide.. To view the entire topic, please sign in or purchase a subscription.. The Harriet Lane. Dolutegravir/Rilpivirine Combination Drug market is inclusive of an in-depth evaluation of this industry, and a commendable brief of its segmentation

Information. Juluca (Dolutegravir and Rilpivirine) is a prescription medication used to treat Human Immunodeficiency Virus (HIV), the virus that can cause Acquired Immunodeficiency Syndrome (AIDS). Juluca is not a cure for HIV or AIDS. Juluca can help prevent HIV from multiplying in your body. Juluca is only for use in people who have been. Dec. 20, 2018. A pill containing two anti-HIV drugs -- dolutegravir + rilpivirine -- has been approved for use in Canada, the European Union and the United States. This pill is sold under the brand name Juluca and is meant to be used as maintenance treatment. With maintenance treatment, a patient first has their HIV viral load suppressed with a.

A once daily single tablet regimen containing integrase inhibitor dolutegravir [see Adis Insight Drug profile 800027913] and non-nucleoside revers External links Cabotegravir.Drug Information Portal.U.S. National Library of Medicine. Rilpivirine.Drug Information Portal.U.S. National Library of Medicine Objective: To review the efficacy and safety of dolutegravir (DTG) with rilpivirine (RPV) as a dual therapy regimen in the treatment of HIV-1 infection.Data Sources: A literature search was performed using PubMed (1966 to January 2019) and Google Scholar (2014 to January 2019) with the search terms dolutegravir, rilpivirine, dual, and switch.Other resources included review articles and the.

Dolutegravir-rilpivirine: first 2-drug regimen for HIV

Due to the regional segmentation, the market is divided into the main regions North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.In addition, the regional analysis covers the breakdown of the market and key players by country The most commonly reported adverse events were nasopharyngitis (10% dolutegravir+rilpivirine, 10% CAR) and headache (8% dolutegravir+rilpivirine, 5% CAR). Adverse events leading to discontinuation in the dolutegravir+rilpivirine group occurred in 3% of patients and 1% in the CAR group

PRIVACY POLICY. Thank you for visiting the HIV/HCV Drug Therapy Guide housed on the Toronto General Hospital Immunodeficiency Clinic Web site. General aggregate user data that will be tracked for both the web-based and mobile applications includes country of origin, new vs. returning visitor to the site, browsers used and sections of the guide that are used most frequently following a full submission: dolutegravir / rilpivirine film-coated tablet (Juluca®) is accepted for use within NHSScotland. Indication under review: The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no. In clinical trials called Sword 1 and Sword 2, researchers tested a combination of dolutegravir + rilpivirine in more than 1,000 participants for up to two years. At the end of this time, 89% of participants taking Juluca had a viral load less than 50 copies/mL, attesting to the combination's power and tolerability David Spach, MD - Find this and other presentations at http://www.hivecho.org/content/presentations#PID=26 Document first published: 12 March 2020. Page updated: 12 March 2020. Topic: Specialised commissioning. Publication type: Policy or strategy, Report. NHS England will commission dolutegravir-rilpivirine for treating HIV-1 in adults in accordance with the criteria outlined in this document

Dolutegravir and rilpivirine Uses, Side Effects & Warnings

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Juluca (ViiV Healthcare UK Ltd), a once-daily, fixed-dose combination of dolutegravir (50 mg) and rilpivirine. dolutegravir/rilpivirine is a topic covered in the Davis's Drug Guide.. To view the entire topic, please log in or purchase a subscription.. Pediatrics Central™ is. A-51-year-old woman developed insomnia, altered mood, paranoid delusions and suicidal attempt during treatment with dolutegravir/rilpivirine

Dolutegravir-rilpivirine is a combination medication used to treat human immunodeficiency virus (HIV) infection and help prevent the human immunodeficiency virus (HIV) from reproducing. HIV is the virus responsible for acquired immune deficiency syndrome (AIDS). HIV infection destroys CD4 (T) cells, which are important to the immune system Introduction. Approximately 37.9 million people worldwide live with HIV and about 25.4 million people use antiretroviral therapy (ART) to manage their infection.1 HIV compromises the immune system by attacking CD4 white blood cells. Without ART, HIV can progress to AIDS, defined as a CD4 count <200 cells/mm 3, increasing the risk for opportunistic infections. If approved, stable, virologically suppressed adults living with HIV-1 could have the option to switch to a single-pill, two-drug regime

Keywords: food effect, pharmacokinetics, dolutegravir, rilpivirine Juluca ® , (ViiV Healthcare) the 2-drug regimen (2-DR) of dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV), administered once daily with a meal has been approved in many countries for the treatment of HIV-1 infection in virologically suppressed patients DOLUTEGRAVIR; RILPIVIRINE (doe loo teg ra veer; RIL pi VIR een) is 2 antiretroviral medicines in 1 tablet. It is used to treat HIV. This medicine is not a cure for HIV. This medicine can lower, but not fully prevent, the risk of spreading HIV to others Juluca is the first complete two-drug HIV regimen. Juluca is manufactured by ViiV Healthcare and Janssen Pharmaceuticals. Dolutegravir is an integrase inhibitor (or INSTI). Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (a non-nuke or NNRTI). These drugs stop HIV from multiplying by preventing the virus' integrase and.

Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Martina Properzi Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy. View further author informatio Guides. Juluca (dolutegravir + rilpivirine) 12 May 2018. Related: Articles, Fixed dose combinations, Integrase inhibitors, NNRTIs. ju-LOO-ka. Juluca is a fixed dose combination (FDC) of dolutegravir (50 mg) and rilpivirine (25 mg).. It is only approved (in the US) as a switch therapy in HIV positive people who have been on stable ART with undetectable viral load for more than six months

A two-drug regimen consisting of once-daily dolutegravir-rilpivirine is effective for maintaining HIV suppression and demonstrates safety similar to that of routine antiretroviral therapy (ART), according to a 48-week, placebo-controlled, randomized trial published in Lancet.. In 2 randomized, non-inferiority, multicenter trials (SWORD-1 and SWORD-2), investigators compared patients with HIV. Pharmacist's Letter includes:. 12 issues every year, with brief articles about new meds and hot topics; 300+ CE courses, including the popular CE-in-the-Letter; Quick reference drug comparison chart HIV Drug Therapy Glasgow 2020; October 5-8, 2020; Virtual Poster 039 Sebastian Noe1, Kevin Ummard-Berger2, Heribert Hillenbrand3, Daniel Beer4, Christoph Wyen5. Overview of AIDS 2018. The Well Project provides a rundown of their own presentations at the International AIDS Conference as well as highlights from other presenters dolutegravir + rilpivirine One tablet once a day. Each tablet contains 50 mg dolutegravir + 25 mg rilpivirine. Take with a meal. ODEFSEY rilpivirine + tenofovir alafenamide + TIVICAY emtricitabine One tablet once a day. Each tablet contains 25 mg rilpivirine + 25 mg tenofovir alafenamide + 200 mg emtricitabine. Take with a meal. TRIUME

Juluca is a complete regimen for the treatment of HIV infection and should not be used with other HIV medicines. Juluca contains the following two different medicines combined in one pill: Dolutegravir -- an HIV medicine called an integrase inhibitor. Rilpivirine -- an HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI. Juluca® (dolutegravir/rilpivirine) is a Integrase inhibitor (INI) and Non-nucleoside reverse transcriptase inhibitor (NNRTI) This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both drugs block the virus from growing and infecting more cells We are open for safe in-person care. Learn more: Mayo Clinic facts about coronavirus disease 2019 (COVID-19) Our COVID-19 patient and visitor guidelines, plus trusted health information Latest on COVID-19 vaccination by site: Arizona patient vaccination updates Arizona, Florida patient vaccination updates Florida, Rochester patient vaccination updates Rochester and Mayo Clinic Health System. ormulations of antiretroviral agents with improved convenience, and better tolerability and efficacy became available. This review aims to update the current experience with the novel two-drug combination of dolutegravir (DTG) and rilpivirine (RPV) and elucidate the possible applications and limitations of coformulated DTG-RPV in the future. Recent findings Five observational studies and two.

DOLUTEGRAVIR; RILPIVIRINE is 2 antiretroviral medicines in 1 tablet. It is used to treat HIV. This medicine is not a cure for HIV. This medicine can lower, but not fully prevent, the risk of spreading HIV to others. The lowest GoodRx price for the most common version of Juluca is around $2,906.05, 19% off the average retail price of $3,604.80 Introduction Brand name: Juluca Generic name: Dolutegravir, rilpivirine Pharmacological class: HIV-1 integrase strand transfer inhibitor (INSTI) + non-nucleoside reverse transcriptase inhibitor Strength and Formulation: 50mg/25mg; tabs Manufacturer: ViiV Healthcare How supplied: Tabs—30 Legal Classification: R Through 148 weeks of the study, there was a low number of confirmed virologic withdrawals (CVWs) across study populations who received dolutegravir + rilpivirine (1%; 11/990) 50mg. tablet for oral suspension (Tivicay PD) 5mg. HIV Infection. Indicated in combination with other ARTs for treatment-naïve or treatment-experienced, but INSTI-naïve children aged ≥4 weeks who weigh ≥3 kg. Weight 3 to <14 kg. Tablets for oral suspension. 3 to <6 kg: 5 mg PO qDay. 6 to <10 kg: 15 mg PO qDay Dolutegravir is used with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 4 weeks of age and older who weigh at least 6.6 lbs (3 kg). It is also used in combination with rilpivirine (Edurant) to treat HIV in certain adults to replace their current HIV medication (s) that has been taken for at least.

Video: Juluca (dolutegravir/rilpivirine) dosing, indications

JULUCA (dolutegravir/rilpivirine

nystatin Anti-infective Antifungal olanzapine Central nervous system Antipsychotic, antimanic omega 3 Cardiovascular, antihyperlipidemic Lipotropic omega 3 (icosapent ethyl) Cardiovascular, antihyperlipidemic Lipotropic omeprazole Gastrointestinal, acid reducing Proton pump inhibitor ondansetron Central nervous system Anti-nausea oseltamivir Anti-infective Anti-influenza antivira Issued: London, UK. ViiV Healthcare today presented three year results from the SWORD 1 & 2 studies, demonstrating that 84% (432/513) of participants who switched from their current three- or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet, 391 (2018), pp. 839-849. Article Download PDF View Record in Scopus Google Scholar. 11 2 Llibre JM, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. The Lancet. 2018 Mar 3;391(10123):839-849 Llibre JM et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Efficacy, safety, and tolerability of dolutegravir

Dolutegravir/rilpivirine - Wikipedi

Initial U.S Approval: 2017 2 Llibre JM, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3. Juluca (dolutegravir, rilpivirine) Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide fumarate) Integrase inhibitors are often used as the initial medications for treating HIV CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210192Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Revie Background. Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to continuing a standard three-drug or four-drug antiretroviral regimen for maintenance of virological suppression in people with HIV-1

Dolutegravir and Rilpivirine (Professional Patient Advice

HIV-1+ individuals initiating DTG/RPV from January 1, 2018 to December 31, 2018 were identified in the OPERA Database. Outcomes were evaluated among the virologically suppressed subgroup who initiated in the first 6 months Dolutegravir-rilpivirine is a single tablet regimen which allows treatment with two drugs rather than three: dolutegravir (an INI), and rilpivirine (an NNRTI). It is a treatment option licensed for people whose HIV is currently controlled (HIV-1 RNA <50 copies/ml) with a stable antiretroviral regimen for at least 6 months, with n

Rilpivirine - WikipediaCore Concepts - Retention in HIV Care - Basic HIV Primary

The SWORD-1 and SWORD-2 studies previously demonstrated that high rates of virologic suppression were maintained for 148 weeks after switching virologically suppressed HIV-1 infected adults from their current 3- or 4-drug antiretroviral regimen (CAR) to the 2-drug regimen (2DR) of dolutegravir + rilpivirine on Day 1 (Early Switch (ES) DTG+RPV group) Of these patients, 1,334 (80%) received treatment with a 3DR regimen (19.9%, 25.0% and 55.1% elvitegravir-, raltegravir- and dolutegravir-based, respectively) and 332 (20%) with a 2DR (79.2% dolutegravir + lamivudine and 20.8% dolutegravir + rilpivirine) regimen dolutegravir, rilpivirine. generic for Juluca combo - integrase inhibitor, non nucleoside RTI. bictegravir, emtricitabine, tenofovir. generic for Biktarvy combo - integrase inhibitor, nucleoside RTI, nucleotide RTI. maraviroc. generic for Selzentry CCR5 Antagonist. enfuvirtide. generic for Fuzeo MDLinx original journal summary on Human Immunodeficiency Virus (HIV), Infectious Disease from Sexually Transmitted Infection

AIDS Drug Assistance Program (ADAP) Formulary, April 1, 2021 14. itraconazole (Sporanox) 15. ketoconazole (Nizoral) 16. leucovorin (Wellcovorin Dolutegravir (doe-loo-TEG-ra-vir), Rilpivirine (ril-pi-VIR-een) Treats HIV infection. This medicine does not cure HIV or AIDS, but it may slow the progress of the disease ^14 SWORD-2 - Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2) The double-blind Oral Mouthwash use to Eradicate GonorrhoeA (OMEGA) trial randomised men who have sex with men to rinse and gargle at least once daily for 60 s with either an antibacterial mouthwash (Listerine; n=219) or a mouth lubricant as control (Biotène; n=227) for a total of 12 weeks.1 2 Oropharyngeal swabs were collected 6-weekly and saliva 3-weekly. The number of incident cases of. Dolutegravir is a drug used for antiviral therapy against HIV. It is manufactured by ViiV Healthcare. Dolutegravir is the third integrase inhibitor drug. When HIV infects a cell, it combines its genetic code into the cell's own code. This is shown in fact sheet 400, step 5

Dolutegravir/Rilpivirine as Simpler Maintenance AfterPredose concentrations of DTG and RPV steady through 100I am a patient | ViiV Healthcare Exchange